查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1578203

全球抗糖尿病市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Antidiabetics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

全球抗糖尿病藥物市場需求預計將從2023年的878億美元達到2032年近2,612.3億美元的市場規模，2024-2032年研究期間複合年成長率為12.88%。

抗糖尿病藥物是用於穩定和控制糖尿病患者血糖水平的藥物。抗糖尿病藥物主要用於控制糖尿病並幫助糖尿病患者維持病情並降低糖尿病的風險。抗糖尿病藥物包括胰島素、普蘭林肽、Byetta、victoza和口服降血糖（錠劑）。

市場動態

糖尿病患者發病率的上升和醫療保健支出的增加是刺激全球抗糖尿病藥物市場成長的基本因素。此外，全球肥胖的流行預計將成為抗糖尿病市場的驅動力。此外，各個重要參與者正採取研發投資和產品推出等業務成長策略，推動抗糖尿病市場的成長。此外，協會和糖尿病協會為提高認知水平並提供有關糖尿病控制的資訊而開展的幾項宣傳和教育計劃運動將刺激進一步的成長。然而，胰島素的成本可能會在一定程度上限制糖尿病市場的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球抗糖尿病藥物市場的各個細分市場進行了包容性評估。抗糖尿病藥物產業的成長和趨勢為本研究提供了整體方法。

市場區隔

抗糖尿病市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按藥品類別範圍

  • 胰島素（長效胰島素、預混胰島素、速效胰島素、人類胰島素）
  • GLP-1 受體激動劑
  • DPP-4抑制劑
  • SGLT2 抑制劑
  • 其他

依糖尿病類型範圍

  • 類型1
  • 2型

依給藥途徑分類 範圍

  • 口服
  • 皮下
  • 靜脈

按配銷通路範圍

  • 網路藥局
  • 醫院藥房
  • 零售藥局

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲抗糖尿病市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。抗糖尿病市場的主要參與者包括阿斯特捷利康公司、拜耳公司、武田製藥有限公司、禮來公司、勃林格殷格翰公司、百時美施貴寶公司、輝瑞公司、強生服務公司、默克公司、諾華公司股份公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

  • 報告說明
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法
    • 市場研究過程
    • 市場研究方法論

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：抗糖尿病藥物 - 產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業動態
  • 波特五力分析
  • 市場吸引力分析
    • 按藥品類別範圍進行的市場吸引力分析
    • 依糖尿病類型範圍進行的市場吸引力分析
    • 按管理範圍分類的市場吸引力分析
    • 按配銷通路範圍分類的市場吸引力分析
    • 市場吸引力分析：按地區

第 4 章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料廠商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：全球抗糖尿病藥物市場分析：按藥物類別範圍

  • 按藥物類別範圍概述
  • 按藥物類別範圍進行歷史和預測數據分析
  • 胰島素（長效胰島素、預混胰島素、速效胰島素、人類胰島素）
  • GLP-1 受體激動劑
  • DPP-4抑制劑
  • SGLT2 抑制劑
  • 其他

第 6 章：全球抗糖尿病藥物市場分析：依糖尿病類型範圍

  • 按糖尿病類型分類的概述範圍
  • 依糖尿病類型範圍進行歷史和預測數據分析
  • 類型1
  • 2型

第 7 章：全球抗糖尿病藥物市場分析：依管理範圍分類

  • 按給藥途徑分類的概述 範圍
  • 按管理範圍分類的歷史和預測資料分析
  • 口服
  • 皮下
  • 靜脈

第 8 章：全球抗糖尿病藥物市場分析：按分銷管道範圍

  • 按配銷通路分類的概述範圍
  • 按配銷通路範圍進行歷史和預測資料分析
  • 網路藥局
  • 醫院藥房
  • 零售藥局

第 9 章：全球抗糖尿病藥物市場分析：依地理位置

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 北美按細分市場銷售分析
    • 北美按國家銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 歐洲按細分市場銷售分析
    • 歐洲按國家銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 亞太地區按細分市場銷售分析
    • 亞太地區按國家銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 拉丁美洲按細分市場銷售分析
    • 拉丁美洲按國家銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 中東和非洲按細分市場銷售分析
    • 中東和非洲按國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東其他地區和非洲銷售分析

第 10 章：抗糖尿病藥物公司的競爭格局

  • 抗糖尿病藥物市場競爭
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他發展

第 11 章：公司簡介

  • 頂級公司市佔率分析
  • 市場集中度
  • AstraZeneca Plc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Bayer AG
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Takeda Pharmaceutical Company Limited
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Eli Lilly And Company
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Boehringer Ingelheim
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Bristol-Myers Squibb
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Pfizer Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Johnson & Johnson Services Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Merck & Co. Inc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Novartis AG
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

Product Code: VMR11218581

The global demand for Antidiabetics Market is presumed to reach the market size of nearly USD 261.23 Billion by 2032 from USD 87.8 Billion in 2023 with a CAGR of 12.88% under the study period 2024-2032.

Antidiabetic drugs are medicines introduced to stabilise and control blood glucose levels in people suffering from diabetes. Antidiabetic drugs are mainly used to manage diabetes and aid diabetic patients in maintaining their condition and lowering their risk of developing diabetes. Antidiabetic drugs include insulin, pramlintide, byetta,victoza and oral hypoglycemics (tablets).

MARKET DYNAMICS

The growing rates of diabetics and rising healthcare expenditure are the fundamental factors that are spurring the growth of the global antidiabetics market. Also, the global prevalence of obesity is expected to serve the antidiabetics market as a driver. Moreover, various significant participants are adopting business growth strategies such as R&D investments and product launches, boosting the antidiabetics market's growth. Furthermore, several campaigns for awareness and education programs created by associations and diabetes societies to raise awareness levels and provide information about diabetes control will stimulate further growth. However, the cost of insulin may limit antidiabetic market growth to some extent.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Antidiabetics. The growth and trends of Antidiabetics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Antidiabetics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class Scope

  • Insulin (Long-acting Insulin, Premix Insulin, Fast-acting Insulin, Human Insulin)
  • GLP-1 Receptor Agonists
  • DPP- 4 Inhibitors
  • SGLT2 Inhibitors
  • Others

By Diabetes Type Scope

  • Type 1
  • Type 2

By Route of Administration Scope

  • Oral
  • Subcutaneous
  • Intravenous

By Distribution Channel Scope

  • Online pharmacies
  • Hospital Pharmacies
  • Retail pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Antidiabetics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Antidiabetics market include AstraZeneca Plc, Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc, Novartis AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. ANTIDIABETICS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class Scope
    • 3.7.2 Market Attractiveness Analysis By Diabetes Type Scope
    • 3.7.3 Market Attractiveness Analysis By Route of Administration Scope
    • 3.7.4 Market Attractiveness Analysis By Distribution Channel Scope
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY DRUG CLASS SCOPE

  • 5.1. Overview By Drug Class Scope
  • 5.2. Historical and Forecast Data Analysis By Drug Class Scope
  • 5.3. Insulin (Long-acting Insulin, Premix Insulin, Fast-acting Insulin, Human Insulin) Historic and Forecast Sales By Regions
  • 5.4. GLP-1 Receptor Agonists Historic and Forecast Sales By Regions
  • 5.5. DPP- 4 Inhibitors Historic and Forecast Sales By Regions
  • 5.6. SGLT2 Inhibitors Historic and Forecast Sales By Regions
  • 5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY DIABETES TYPE SCOPE

  • 6.1. Overview By Diabetes Type Scope
  • 6.2. Historical and Forecast Data Analysis By Diabetes Type Scope
  • 6.3. Type 1 Historic and Forecast Sales By Regions
  • 6.4. Type 2 Historic and Forecast Sales By Regions

7. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION SCOPE

  • 7.1. Overview By Route of Administration Scope
  • 7.2. Historical and Forecast Data Analysis By Route of Administration Scope
  • 7.3. Oral Historic and Forecast Sales By Regions
  • 7.4. Subcutaneous Historic and Forecast Sales By Regions
  • 7.5. Intravenous Historic and Forecast Sales By Regions

8. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL SCOPE

  • 8.1. Overview By Distribution Channel Scope
  • 8.2. Historical and Forecast Data Analysis By Distribution Channel Scope
  • 8.3. Online pharmacies Historic and Forecast Sales By Regions
  • 8.4. Hospital Pharmacies Historic and Forecast Sales By Regions
  • 8.5. Retail pharmacies Historic and Forecast Sales By Regions

9. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ANTIDIABETICS COMPANIES

  • 10.1. Antidiabetics Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF ANTIDIABETICS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. AstraZeneca Plc
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Bayer AG
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Takeda Pharmaceutical Company Limited
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Eli Lilly And Company
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Boehringer Ingelheim
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Bristol-Myers Squibb
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Pfizer Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Johnson & Johnson Services Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Merck & Co. Inc
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Novartis AG
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Class Scope (USD MN)
  • Insulin (Long-acting Insulin, Premix Insulin, Fast-acting Insulin, Human Insulin) Market Sales By Geography (USD MN)
  • GLP-1 Receptor Agonists Market Sales By Geography (USD MN)
  • DPP- 4 Inhibitors Market Sales By Geography (USD MN)
  • SGLT2 Inhibitors Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Diabetes Type Scope (USD MN)
  • Type 1 Market Sales By Geography (USD MN)
  • Type 2 Market Sales By Geography (USD MN)
  • Analysis By Route of Administration Scope (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Subcutaneous Market Sales By Geography (USD MN)
  • Intravenous Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel Scope (USD MN)
  • Online pharmacies Market Sales By Geography (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail pharmacies Market Sales By Geography (USD MN)
  • Global Antidiabetics Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Antidiabetics Report
  • Market Research Process
  • Market Research Methodology
  • Global Antidiabetics Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Class Scope
  • Market Attractiveness Analysis By Diabetes Type Scope
  • Market Attractiveness Analysis By Route of Administration Scope
  • Market Attractiveness Analysis By Distribution Channel Scope
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Class Scope (USD MN)
  • Insulin (Long-acting Insulin, Premix Insulin, Fast-acting Insulin, Human Insulin) Market Sales By Geography (USD MN)
  • GLP-1 Receptor Agonists Market Sales By Geography (USD MN)
  • DPP- 4 Inhibitors Market Sales By Geography (USD MN)
  • SGLT2 Inhibitors Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Diabetes Type Scope (USD MN)
  • Type 1 Market Sales By Geography (USD MN)
  • Type 2 Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration Scope (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Subcutaneous Market Sales By Geography (USD MN)
  • Intravenous Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel Scope (USD MN)
  • Online pharmacies Market Sales By Geography (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail pharmacies Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.